Processes
Scientific Studies
Since its establishment, STR Biotechnologies has been actively engaged in supporting scientific advancement in the fields of regenerative medicine, biotechnology, and cellular therapy systems. Research focused on the effective use of blood-, platelet-, and adipose tissue-derived biological components in tissue repair and regenerative treatments is conducted in collaboration with experienced physicians, academic researchers, and international partners.
In addition to its in-house R&D and laboratory infrastructure, STR Biotechnologies collaborates with national and international laboratories to contribute to the development of scientific protocols and innovative treatment approaches. Through these collaborations, the company continuously expands its scientific knowledge base and supports evidence-based innovation.
Guided by scientific findings and clinical insights, STR Biotechnologies develops next-generation medical technologies and innovative systems in the fields of PRP, PRF, CGF, SVF, exosome technologies, and regenerative medicine. By combining research, engineering, and biotechnology expertise, the company is committed to advancing healthcare through reliable, effective, and scientifically driven solutions.
Placing scientific excellence at the core of its corporate culture, STR Biotechnologies prioritizes efficacy, safety, and clinical applicability throughout every stage of product development. Through its research-driven approach, the company develops innovative solutions that address the evolving needs of healthcare professionals while contributing to technological advancement in regenerative medicine.
STR Biotechnologies actively supports and participates in:
• Scientific Congresses and International Conferences
• Academic Research Programs
• Clinical Studies and Scientific Investigations
• Educational and Professional Training Programs
• Workshops and Hands-On Training Activities
By fostering collaboration between science, clinical practice, and technology, STR Biotechnologies contributes to the continuous advancement of regenerative medicine and biotechnology.
Each year, the company invests significant resources into research and development, scientific studies, and innovation initiatives. Through this commitment, STR Biotechnologies aims to drive sustainable innovation, accelerate scientific progress, and contribute to the development of next-generation regenerative medicine technologies that will shape the future of healthcare.
Certification & Regulatory Compliance
STR Biotechnologies manages quality and regulatory processes with a holistic approach, starting from the product development phase. Quality and regulatory experts within the company conduct design files, technical documentation, risk analyses, clinical evaluation reports, performance tests, and validation processes in accordance with international standards.
To confidently offer its products in the global market, STR Biotechnologies is working towards international certification and compliance processes such as:
MDR CE (European Conformity)
FDA
GMP
ISO 13485
KFDA
CFDA
SFDA
and ensuring the compliance of its products with regulatory requirements in different markets.
Operating with a continuous improvement mindset, STR Biotechnologies constantly updates its quality management systems by closely monitoring changing global regulations and industry standards. In this context, it strengthens its quality culture, increases technical competence, and creates an organizational structure ready for future regulatory processes by offering regular training programs to its employees.
With its production infrastructure compliant with international quality standards and strong regulatory management, STR Biotechnologies aims to become a reliable biotechnology brand on a global scale.
Trainings
STR Biotechnologies conducts educational activities that support knowledge sharing in the fields of regenerative medicine and biotechnology. Through dealer, distributor, and physician training programs organized both domestically and internationally, professional support is provided regarding proper product usage, clinical applications, and marketing processes.
Through workshops, webinars, and hands-on training programs conducted with experienced healthcare professionals and key opinion leaders, STR Biotechnologies aims to help medical professionals effectively and safely utilize the latest technologies and treatment approaches.
With its education-focused approach that promotes scientific advancement, STR Biotechnologies contributes to the sustainable exchange of knowledge and the continuous development of regenerative medicine practices worldwide.
Manufacturing
STR Biotechnologies operates highly controlled manufacturing processes for regenerative medicine and biotechnology products through its modern production infrastructure built in accordance with international quality standards.
Within its clean room facilities, the company performs plastic injection molding, vacuum tube filling and assembly, ultrasonic welding, blister forming, siliconization, pad printing, washing, drying, polymer gel production, dosing, packaging, and labeling processes.
STR Biotechnologies also manages sterilization processes within its own manufacturing infrastructure, ensuring reliable, sustainable, and compliant production in accordance with medical device manufacturing standards.
The company collaborates with business partners across Türkiye and various international markets for the production of plastic, silicone, rubber, and metal components. Through its OEM and Private Label manufacturing models, STR Biotechnologies provides production support to numerous healthcare brands worldwide.
With advanced manufacturing technologies, a quality-focused approach, and strong engineering capabilities, STR Biotechnologies continues to operate as a trusted biotechnology manufacturer serving both domestic and international markets.
Marketing
STR Biotechnologies represents its biotechnology and regenerative medicine products, developed and manufactured in Türkiye, with a strong global brand vision. In addition to its own product portfolio, the company actively promotes and markets products developed through OEM and Private Label partnerships with international business partners, supporting healthcare brands worldwide.
STR Biotechnologies regularly participates in leading international medical congresses and exhibitions, including MEDICA, AMWC, IMCAS, EFORT, KIMES, and Dubai Derma, showcasing its innovative technologies to the global healthcare community. The company also actively supports and participates in numerous scientific congresses and professional events in Türkiye across the fields of orthopedics, dermatology, plastic surgery, physical medicine and rehabilitation, and medical aesthetics.
Through its scientific approach, innovative product technologies, and strong international partnerships, STR Biotechnologies continues to strengthen its presence and achieve sustainable growth in global healthcare markets.
R&D and Innovation
STR Biotechnologies combines scientific expertise with advanced engineering capabilities to develop innovative medical devices for regenerative medicine and biotechnology applications. Focused on making clinical procedures safer, more effective, and user-friendly, the company continuously works on technologies that facilitate the integration of scientific protocols into everyday clinical practice.
From the earliest stages of product development, engineering design processes, 3D modeling, prototyping, performance testing, and validation activities are carried out in accordance with internationally recognized quality standards. This systematic approach ensures that every product meets the highest expectations for safety, functionality, and reliability.
By managing all research, development, and manufacturing operations in line with the principles of the ISO 13485 Medical Devices Quality Management System, STR Biotechnologies is committed to developing reliable, sustainable, and high-performance medical technologies that support healthcare professionals and advance the future of regenerative medicine.